Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on December 11, 2025. The filing was submitted on December 12, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full-period financial results. Key metrics for the transaction on December 11, 2025, include:
- Shares Purchased: 217,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,793.00 GBp; highest price paid was 1,820.00 GBp.
- Average Price: Volume-weighted average price paid was 1,807.53 GBp.
- Trading Venues: Purchases were executed across BATE (17,501 shares), CHIX (65,566 shares), and XLON (133,933 shares).
Capital Structure Impact:
- Treasury Shares: Following this purchase, the Company holds 238,626,577 ordinary shares in treasury.
- Shares in Issue: 4,076,812,560 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.85% of the total voting rights.
- Programme Progress: Since September 30, 2025, the Company has purchased a total of 13,161,733 ordinary shares.
Material Changes
The filing does not report material changes to revenue, profit, or operating margins. The primary change reported is the reduction in the number of shares in issue and the increase in treasury shares resulting from the buyback activity. The percentage of voting rights held in treasury increased to 5.85% following this transaction.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's 2024 Annual Report on Form 20-F and Q3 2025 Results. The purchase was executed pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the updated share count and treasury percentage (5.85%) for dividend and voting calculations.
- Review the 2024 Form 20-F and Q3 2025 Results for the risk factors referenced in the cautionary statement.
- Monitor subsequent 6-K filings for further updates on the buyback programme progress.